CREATION.co

How to launch a blockbuster drug in severe #asthma? Jessica Fernandes reflects on what we learned from the online HCP conversation about GSK's #depemokimab and offers some timely tips to support the launch. Read the full article: How social media intelligence can support blockbuster launches: GSK’s depemokimab https://lnkd.in/empj74nk #WhatHCPsThink #sociallistening #medicine #asthma

How do platforms like Veeva Link, IQVIA Expert Ecosystem, and CREATION’s DOL Finder compare when it comes to identifying healthcare professionals (HCPs) and digital opinion leaders (DOLs)? 🤔 In our recent #IBD DOL Finder demo webinar, we briefly explored this question: Veeva Link & IQVIA Expert Ecosystem shine in identifying traditional academic KOLs, offering rich profiles of clinical trial leaders and publishers. CREATION's DOL Finder stands apart by analyzing true digital peer influence — showing how HCPs impact each other in social spaces. It’s not just about being online; it’s about driving meaningful peer-to-peer conversations. Register to watch the webinar on demand now: https://lnkd.in/eFQ4NCFs Or read our in-depth article exploring this comparison written by Daniel Ghinn: https://lnkd.in/eQPCt-_5 #DOLFinder #HCPInsights #DigitalLeadership #OnDemandWebinar #HealthcareInnovation

On September 27, the FDA approved Sanofi and Regeneron’s dupilumab (dupixent) for individuals with chronic obstructive pulmonary disease (COPD) - the first biologic medicine for patients with the disease to be approved in the US, reports Timothy Smith in HCPLive. “This latest FDA approval represents new hope for the hundreds of thousands of COPD patients in the U.S. who can sometimes struggle just to breathe during their everyday lives,” george yancopoulos, MD, PhD, president and chief scientific officer at Regeneron, and principal inventor of dupilumab, said in a statement. In our September COPD Tracker, we identified 18 posts from US HCPs about COPD medications, a rise of 41.6 per cent on the rolling monthly average. Among these was a post by Surya P Bhatt, MD, who described news of dupilumab’s approval as a “truly groundbreaking moment” for those suffering with COPD. Read more about what we heard in our COPD Tracker last month: https://lnkd.in/eJ9FrHNN #COPD #dupilumab #WhatHCPsThink

Behind the scenes with Daniel Ghinn and Bernard G. preparing for our insightful #IBD webinar! The discussion is now available on demand — dive into the latest trends in Digital Opinion Leaders and online HCPs in IBD. Whether you missed the live session or want to revisit key moments, you can now watch it anytime! Register now to access to this demo webinar on demand: https://lnkd.in/eFQ4NCFs #IBD #HealthcareInnovation #WebinarOnDemand #DigitalHealth

We are grateful to see CREATION.co featured in a recent article exploring the evolution of social media in pharma and healthcare marketing. Beth Snyder Bulik' piece highlights how platforms like #TikTok, #LinkedIn, #Instagram, and others are transforming how healthcare professionals and organizations communicate and connect. Our research provided insights into the ways healthcare professionals utilize these platforms—for patient education, professional networking, advocacy, and more. It’s exciting to see the growing recognition of the unique roles each platform plays in advancing healthcare communication. Acknowledging the incredible impact of social media in fostering meaningful engagement across the healthcare ecosystem is a step toward more innovative and effective strategies. Read the full piece: https://lnkd.in/eBqfA96M #PharmaMarketing #SocialMedia #HealthcareInnovation #HCPEngagement

On October 3, the FDA extended the approval of Bristol Myers Squibb’s nivolumab for the treatment of adult patients with resectable non-small cell lung cancer following the results of the CHECKMATE 77T trial, reports Gillian McGovern in Pharmacy Times. Tina Cascone, MD, PhD, associate professor of Thoracic/Head and Neck Medical Oncology at the University of Texas MD Anderson Cancer Center, said the approval was a “step forward" for patients with resectable disease. In our Product Launch Tracker this October, we found that 33 HCPs posted 41 posts sharing news of the approval on X. Medical oncologist Iván Gonzalez, celebrated the approval, acknowledging nivolumab to be “a promising option for stage IIA-IIIB NSCLC patients.” Read more about what we heard in our Product Launch Tracker last month: https://lnkd.in/eN6aV62k #lungcancer #FDA #cancer #medicine

In our breast cancer #DOLFinder Demo, we highlighted Dr. Tarantino as a leading Digital Opinion Leader (DOL) in the field. With over 916 mentions in the breast cancer online conversation by #healthcare professionals, and more than 2,000 amplifications of his breast cancer posts online by other HCPs. Our demo showcased how key figures like Dr. Taloney and Dr. Ambika actively engage with and amplify Dr. Tarantino’s contributions, confirming his significant impact within the breast cancer medical community. Stay connected to the developments in breast cancer during #SABCS24 this week. #breastcancer #oncology #hcp #DOL

Our #IBD DOL Finder demo webinar hosted by Daniel Ghinn and Bernard G. is now available on demand. This comprehensive session provides in-depth insights into advanced strategies for identifying and engaging with online #HCPs in breast cancer. By registering, you’ll gain access to the full recording. Click here to register and watch now: https://lnkd.in/eFQ4NCFs

Don't know which healthcare professionals (HCPs) to invest in before, during and after #congress? Ahead of #SABCS24, Daniel Ghinn and Anni Neumann dive into the power of social media listening in our on-demand webinar, "Unlocking Hidden HCP Influence at congress." Discover how CREATION Pinpoint can help uncover the hidden impact of #HCPs at medical congresses. Gather more of these insights in our on-demand webinar. Register now to access the full webinar: https://lnkd.in/d2-qY-M4

In our Better Listening for Better Health podcast, CREATION.co CEO Daniel Ghinn speaks with Prof. Partha S Kar about how social media drives change in #diabetes care. Prof. Kar highlights how platforms like X, Facebook, and LinkedIn help him: 🔹 Share key information and science advancements 🔹 Connect with policymakers and patients 🔹 Foster authentic, impactful conversations His advice for HCPs? Start by observing both those you admire and those you don’t to gain a balanced perspective. Assess where you fit in, post respectfully to build your reputation, and once established, don’t shy away from sharing differing opinions authentically. Read the summary of the interview: https://lnkd.in/eM67r7WM #DigitalHealth #BetterListeningForBetterHealth